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Eﬀ ect of candesartan on progression and regression of 
retinopathy in type 2 diabetes (DIRECT-Protect 2): 
a randomised placebo-controlled trial
Anne Katrin Sjølie, Ronald Klein, Massimo Porta, Trevor Orchard, John Fuller, Hans Henrik Parving, Rudy Bilous, Nish Chaturvedi, for the 
DIRECT Programme Study Group*
Summary
Background Diabetic retinopathy remains a leading cause of visual loss in people of working age. We examined 
whether candesartan treatment could slow the progression and, secondly, induce regression of retinopathy in people 
with type 2 diabetes.
Methods We did a randomised, double-blind, parallel-group, placebo-controlled trial in 309 centres worldwide. We 
recruited normoalbuminuric, normotensive, or treated hypertensive people with type 2 diabetes with mild to 
moderately severe retinopathy and assigned them to candesartan 16 mg once a day or placebo. After a month, the 
dose was doubled to 32 mg once per day. Investigators and patients were unaware of the treatment allocation status. 
Progression of retinopathy was the primary endpoint, and regression was a secondary endpoint. Analysis was by 
intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00252694.
Findings 1905 participants (aged 37–75 years) were randomised to candesartan (n=951) or placebo (n=954). 161 (17%) 
patients in the candesartan group and 182 (19%) in the placebo group had progression of retinopathy by three steps 
or more on the Early Treatment Diabetic Retinopathy Study scale. The risk of progression of retinopathy was non-
signiﬁ cantly reduced by 13% in patients on candesartan compared with those on placebo (hazard ratio [HR] 0·87, 
95% CI 0·70–1·08, p=0·20). Regression on active treatment was increased by 34% (1·34, 1·08–1·68, p=0·009). HRs 
were not attenuated by adjustment for baseline risk factors or changes in blood pressure during the trial. An overall 
change towards less severe retinopathy by the end of the trial was observed in the candesartan group (odds 1·17, 
95% CI 1·05–1·30, p=0·003). Adverse events did not diﬀ er  between the treatment groups.
Interpretation Treatment with candesartan in type 2 diabetic patients with mild to moderate retinopathy might induce 
improvement of retinopathy. 
Funding  AstraZeneca and Takeda.
Introduction
Diabetic eye disease, including retinopathy with macular 
oedema, remains the leading cause of blindness in people 
of working age.1,2 At diagnosis, nearly 40% of people with 
type 2 diabetes already have some degree of retinopathy; 
another 22% will develop it over 6 years.3 
Strict glycaemic control and control of blood pressure 
in those with hypertension substantially reduce the 
progression of diabetic eye disease.4–6 Lowering blood 
pressure, can also be of beneﬁ t, even in normotensive 
patients,6 although retinopathy has not been tested as a 
primary outcome. Optimal control of blood glucose and 
blood pressure, however, is not achievable in all patients 
with type 2 diabetes7,8 and, even when obtained, is not 
always eﬀ ective.9 Laser photocoagulation can reduce the 
risk of blindness from proliferative retinopathy,10 but is 
less eﬀ ective for treatment of diﬀ use macular oedema,11 
and has side-eﬀ ects.10 
The speciﬁ c role of blockade of the renin–angiotensin 
system has not been studied in retinopathy in type 2 
diabetes, whereas it has been shown to reduce risks for 
nephropathy and cardiovascular disease.12–17 Angiotensin 
receptor blockers are now recommended for people with 
type 2 diabetes with microalbuminuria or macro-
albuminuria,18 and might prevent development of 
microalbuminuria in hypertensive patients with type 2 
diabetes.19 We designed three separate randomised, 
double-blind, placebo-controlled clinical trials to assess 
whether the angiotensin receptor blocker candesartan 
could reduce the incidence of retinopathy in type 1 
diabetes (DIabetic REtinopathy Candesartan Trials 
[DIRECT]-Prevent 1); progression of retinopathy in type 1 
diabetes (DIRECT-Protect 1); and progression of 
retinopathy in type 2 diabetes (DIRECT-Protect 2). In this 
paper, we report the ﬁ ndings of the third trial.
Methods
Participants
The study design and baseline data have previously been 
described in detail.20,21 We screened men and women who 
were aged 37–75 years and had known type 2 diabetes for 
between 1 and 20 years in 309 centres worldwide. 
Inclusion criteria were age at onset of 36 years or older, 
and no need for continuous insulin treatment within a 
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year of diagnosis. We excluded patients who had eye 
conditions that precluded capture of gradable retinal 
photographs (ie, dense cataracts and angle-closure 
glaucoma); those with clinically signiﬁ cant macular 
oedema or proliferative retinopathy, and those who had 
stenotic valvular heart disease, recent stroke, or myocardial 
infarction. We also excluded pregnant and lactating 
women, and patients with renal impairment (women 
with serum creatinine >110 μmol/L and men with serum 
creatinine >130 μmol/L).
We obtained two overnight urine samples, which were 
analysed for albumin at a central laboratory, using 
nephelometry. Patients were excluded if results showed 
that urinary albumin excretion rate in at least one of the 
two samples was not less than 20 μg/min, indicating 
normoalbuminuria. If patients were not on antihyper-
tensive treatment, they had to have systolic/diastolic blood 
pressure of less than or equal to 130/85 mm Hg; or if they 
were on antihypertensive treatment, a blood pressure of 
less than or equal to 160/90 mm Hg. Patients who were 
taking renin–angiotensin system inhibitors were 
excluded. Patients also had to have mild to moderately 
severe non-proliferative diabetic retinopathy, assessed by 
a score of 20/10 or more and 47/47 or less on the severity 
scale used in the Early Treatment Diabetic Retinopathy 
Study (ETDRS; table 1).22,23 
Conduct of the study was overseen by a steering 
committee. The programme was approved by national 
and local ethics committees and regulatory bodies at all 
participating centres. An independent safety committee 
regularly reviewed safety data. All patients provided 
written informed consent. 
Procedures
Random assignment was done centrally, using an 
interactive voice-response system. Both investigators and 
participants were unaware of the treatment allocation of 
each participant. Participants were randomly assigned to 
receive candesartan 16 mg once a day or matching placebo. 
After a month, this dose was doubled to 32 mg once a day 
of either treatment. An adjustment to 16 mg once a day or 
8 mg once a day could be made at any time during the 
study. We assessed blood pressure and adverse events 
every 6 months, and did all other tests once a year and at 
the ﬁ nal visit. All participants were followed up for at least 
4 years. 
We took retinal photographs at 6 months, 1 year, and 
every year thereafter. Seven-ﬁ eld stereo photographs of 
both eyes were taken according to the ETDRS protocol.22,23 
Two grading teams of independent observers, each 
consisting of a primary and a secondary grader, were 
assigned to each patient for the duration of the study at 
the Retinopathy Grading Centre, Imperial College 
London, UK. Graders, who were unaware of treatment 
allocation, assessed all photographs for retinopathy. The 
ETDRS scale has 11 assignable levels of increasing 
severity for retinopathy (table 1). Each eye was graded 
separately. The Academic Coordinating Centre, Imperial 
College London, UK undertook regular quality assurance 
cycle procedures to test reliability and repeatability. Each 
grading team was asked to assess a master set of 
52 fundus photograph sets (104 eyes), across the range of 
4717 patients assessed for eligibility
1905 randomised
2812 ineligible
 2069 did not meet inclusion criteria 
    273 withdrew consent
    470 other reasons
144 discontinued
 82 withdrew consent 
 37 died
   8 lost to follow-up
 17 other reasons
154 discontinued
 90 withdrew consent 
 35 died
 10 lost to follow-up
 19 other reasons
951 assigned  
 candesartan
954 assigned 
 placebo
951 available for intention-
         to-treat analysis
954 available for intention-
         to-treat analysis
Figure 1: Trial proﬁ le
Severity Deﬁ nition
10 DR absent All DR features absent
20 MA only MA(s) only, other lesions absent
35 Mild NPDR MA plus retinal haemorrhage(s), HEs, or CWSs
43 Moderate 
NPDR
Lesions as above and either extensive or severe 
HMAs or IRMAs present
47 Moderately 
severe NPDR
Lesions of level 35 and either extensive or 
severe HMAs with IRMAs or venous beading
53 Severe NPDR Extensive and severe HMAs, IRMAs or, venous 
beading, or both
61, 65, 
71, 75, 81 
PDR NVD or NVE, or both, without or with 
complications
Clinically signiﬁ cant macular oedema (CSME) was graded according to the criteria 
in the DIRECT Programme—ie, 0=no evidence of CSME; 1=questionable presence 
of CSME; 2=non-CSME but macular thickening; 3=deﬁ nite CSME due to retinal 
thickening of at least one disc area, any part of which lies within one disc diameter 
from the fovea; and 4=deﬁ nite CSME due to thickening or hard exudates less than 
500 μm from the fovea. CWSs=cotton-wool spots. DR=diabetic retinopathy. 
HEs=hard exudates. HMAs=haemorrhages and microaneurysm. 
IRMAs=intraretinal microvascular abnormalities. MA=microaneurysms. 
NPDR=non-proliferative diabetic retinopathy. NVD=new vessels on the optic disc. 
NVE=new vessels elsewhere. PDR=proliferative diabetic retinopathy.
Table 1: Severity and lesions deﬁ ning level on the Early Treatment 
Diabetic Retinopathy Study scale used for the DIabetic REtinopathy 
Candesartan Trials (DIRECT) Programme 
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retinopathy severity, without knowing whether it was 
part of the quality assurance cycle procedure or the study. 
Each team assessed the master set six times throughout 
the trial. Unweighted interteam kappa statistics between 
teams were 0·73, 0·63, 0·67, 0·67, 0·63, and 0·68 for the 
six cycles, and agreement within teams (comparing 
current with baseline or previous cycle) varied from 0·64 
to 0·79 (median 0·74).
Other standardised procedures included automated 
measurement of blood pressure (Omron M4, Omron 
Healthcare, Kyoto, Japan) in the seated position after 
5 min of rest. Three measurements were taken, and 
the mean of the last two measurements was used in 
the analysis. Blood samples were taken for measure-
ments of HbA1c, serum total cholesterol, HDL 
cholesterol, and creatinine. All assays were done at a 
central laboratory. 
The primary endpoint was progression of retinopathy, 
deﬁ ned as an increase in three or more ETDRS levels (ie, 
at least two steps in one eye and one step in the other, or at 
least three steps in one eye with the other remaining 
unchanged).20 An additional prespeciﬁ ed outcome 
measure was overall change in retinopathy levels from 
baseline to ﬁ nal visit, by treatment group.
Secondary endpoints were regression of retinopathy 
(deﬁ ned as a reduction of at least three or more steps on 
the ETDRS scale from baseline to any follow-up visit, or 
two or more steps sustained at two consecutive follow-up 
visits); and development of proliferative diabetic 
retinopathy, clinically signiﬁ cant macular oedema, or 
both. Clinically signiﬁ cant macular oedema was 
diagnosed as retinal thickening of one or more disc area 
(any part of which lies less than a disc diameter from the 
fovea) or hard exudates less than 500 μm from the fovea.
Statistical methods 
We planned to include 1700 patients with a follow-up of at 
least 3 years. The calculated power to detect a 27% reduc-
tion due to treatment in three-step or more progression of 
retinopathy was estimated to be approximately 80% at 
5% signiﬁ cance level.21 The study was extended by 1 year 
because the event rate was lower than expected. We 
analysed all patients according to intention to treat, and 
calculated all p values without adjustment due to the 
prespeciﬁ ed hierarchical testing strategy.
The primary outcome was the time from baseline to 
the ﬁ rst occurrence of an increase of at least three steps 
on the ETDRS scale. The exact time of an event was not 
known more precisely than the time between two fundus 
photographs. Therefore, we used the non-parametric 
generalised log-rank test for the primary analysis, to 
compare the distributions of the time to an event for 
placebo and candesartan.24 Non-parametric maximum 
likelihood estimators for censored data enabled these 
distributions to be shown on a graph.25 To estimate the 
treatment eﬀ ect, we calculated 95% CIs for the hazard 
ratio (HR) using a generalisation of a Cox-regression 
model.26 If a photograph for only one eye was missing at 
a visit, we used the photograph from the previous visit. 
We used a Wilcoxon-Mann-Whitney test to assess 
whether the distribution of the change in severity 
of retinopathy from baseline diﬀ ered by treatment. 
Candesartan (N=951) Placebo (N=954)
Men 466 (49%) 482 (51%)
Age (years) 56·9 (7·6) 56·8 (7·9)
Caucasian 916 (96·3%) 914 (95·8%)
Retinopathy level in worst eye (ETDRS scale)
 10 4 (0%) 1 (0%)
 20 271 (28%) 273 (29%)
 35 532 (56%) 502 (53%)
>35 144 (15%) 178 (19%)
Duration of diabetes (years) 8·8 (4·9) 8·7 (4·8)
Treatment for diabetes 
No pharmacological treatment 22 (2%) 20 (2%)
Insulin only 159 (17%) 170 (18%) 
Oral hypoglycaemic agent only 592 (62%) 581 (61%)
Insulin and oral hypoglycaemic agent 178 (19%) 183 (19%)
HbA1c (%) 8·2 (1·6) 8·2 (1·6)
Treated for hypertension 588 (62%) 592 (62%)
Systolic blood pressure (mm Hg) normotensive 123 (8·7) 123 (9·0)
Treated hypertensive 139 (12·7) 139 (12·0)
Diastolic blood pressure (mm Hg) normotensive 75 (6·4) 76 (6·5)
Treated hypertensive 79 (6·9) 80 (7·1)
Body-mass index (kg/m²) 29·4 (4·6) 29·4 (4·8)
Total serum cholesterol (mmol/L) 5·3 (1·1) 5·3 (1·1)
Serum non-HDL lipoprotein cholesterol (mmol/L) 3·9 (1·0) 3·9 (1·1)
Serum creatinine (μmol/L) 90·3 (15·5) 90·1 (15·2)
Urinary albumin excretion rate (μg/min) 5·5 (3·5, 8·5) 5·5 (3·5, 8·5)
Smoking (ex-smoker or current) 253 (27%) 259 (27%)
Cardiovascular disease   
Previous myocardial infarction 49 (5%) 50 (5%)
Previous stroke 16 (2%) 10 (1%)
Data are mean (SD), number (%), or median (IQR). OHA=oral hypoglycaemic agents. ETDRS=Early Treatment Diabetic 
Retinopathy Study. 
Table 2: Baseline characteristics
0
0
0·1
0·2
0·3
0·4
1 2 3 5 64
Candesartan
Placebo
Number at risk
Placebo
Candesartan
Time from randomisation (years)
954
951
845
848
794
807
737
737
513
540
112
123
3
0
p=0·1994
Figure 2: Cumulative proportion of patients with progression of retinopathy by treatment allocation 
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We calculated the corresponding odds between treat-
ments.27 
The trial is registered with ClinicalTrials.gov, number 
NCT00252694.
Role of funding source
The sponsors of the study did the statistical analysis, with 
validation by an independent statistician. Data were 
gathered by investigators, and data management was 
done by ICON on behalf of the sponsors. The study 
protocol was designed by members of the steering 
committee. The authors had full access to all data, and 
were free to interpret the data, and draw conclusions. 
The corresponding author had full access to all data, and 
had ﬁ nal responsibility for the decision to submit for 
publication.
Results
Figure 1 shows the trial proﬁ le. Randomisation 
commenced in August, 2001, and was completed in 
February, 2004. The last patient was evaluated in March, 
2008. Median follow-up was 4·7 years. Table 2 shows that 
baseline clinical characteristics did not diﬀ er between 
placebo and candesartan groups.
688 (36%) of 1905 patients were receiving insulin 
treatment at randomisation, and 1015 (53%) during the 
study, with no diﬀ erence between treatment groups. Of 
1015 receiving insulin during the study, 501 patients were 
treated with candesartan and 514 were treated with 
placebo (p=0·60). HbA1c concentrations were stable over 
time, with no diﬀ erence in mean values between the 
treatment groups (p=0·48).
At baseline, 1180 (62%) of 1905 patients were treated for 
hypertension with medication other than inhibitors of 
the renin–angiotensin system, and with an almost equal 
distribution of β blockers, diuretics, and calcium-
antagonists. During the study, 685 (72%) of 951 patients 
in the candesartan group and 731 (77%) of 954 patients in 
the placebo group were on any antihypertensive treat-
ment (p=0·026). 196 (21%) in the candesartan group and 
271 (28%) in the placebo group were treated with 
renin–angiotensin system inhibitors (p<0·0001). 
818 (86%) patients were taking the maximum candesartan 
dose of 32 mg at the end of the study.
The mean change in systolic/diastolic blood pressure 
was 4·3/2·5 mm Hg greater in the candesartan group 
than in the placebo group at the ﬁ nal visit for patients 
who were receiving antihypertensive treatment at 
baseline (p<0·0001 for both). For those not on such 
treatment, the diﬀ erence in change was 2·9/1·3 mm Hg 
(p=0·0003/p=0·0045). The reduction in blood pressure 
was observed within 2 months after random assignment 
and persisted for the duration of the trial.
161 (17%) of 951 patients in the candesartan group and 
182 (19%) of 954 in the placebo group had progression of 
retinopathy by three steps or more on the ETDRS scale—
the primary outcome (HR 0·87, 95% CI 0 ·70–1·08, 
p=0·20) (ﬁ gure 2; table 3). Adjustment for baseline 
covariates, with systolic blood pressure and HbA1c as 
time-dependent variables did not change the HR. 
Separate assessment of these variables showed that HbA1c 
and retinopathy at baseline aﬀ ected the progression of 
retinopathy (data not shown). Figure 3 shows that 
participants in the candesartan group were more likely to 
have an overall improvement in retinopathy by the end of 
the trial than those in the placebo group (odds 1·17, 
95% CI 1·05–1·30, p=0·003).
180 (19%) of 951 participants in the candesartan group 
and 136 (14%) of 954 controls had regression of retinopathy, 
Hazard ratio (95% CI) p value
Unadjusted 0·87 (0·70–1·08) 0·199
Adjusted* 0·86 (0·69–1·06) 0·156
Adjusted† 0·89 (0·72–1·10) 0·288
*Adjusted for the following baseline characteristics: retinopathy level, duration of diabetes, urinary albumin excretion 
rate, HbA1c, antihypertensive treatment, and systolic blood pressure. †Adjusted for the following baseline 
characteristics: retinopathy level, duration of diabetes, urinary albumin excretion rate, HbA1c, antihypertensive 
treatment, and systolic blood pressure as a time-dependent covariate.
Table 3: Estimated hazard ratios for candesartan versus placebo for time to three-step progression of 
retinopathy (intention-to-treat population) 
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Figure 3: Distribution of changes in ETDRS level during study, by treatment group
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Figure 4: Cumulative proportion of patients with regression of retinopathy, by treatment group
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which showed that candesartan was associated with a 34% 
increase in the relative chance of regression (p=0·009) 
(ﬁ gure 4; table 4). This beneﬁ cial eﬀ ect was not altered by 
baseline covariates or change in systolic blood pressure 
during the study (table 4). Analysis of the relation between 
retinopathy at baseline and the chance of regression 
(ﬁ gure 5) showed that the treatment eﬀ ect was signiﬁ cant 
in patients with mild retinopathy (level 35), but not in 
those with moderate to moderately severe retinopathy 
(p=0·064 for interaction). From these data, 21 patients 
would need to be treated with candesartan for 4·7 years to 
obtain regression of retinopathy in one patient.
192 (20%) of 951 patients in the candesartan group and 
193 (20%) of 954 controls had proliferative diabetic 
retinopathy, clinically signiﬁ cant macular oedema, or 
both (HR 0·971, p=0·773). 
Adverse events did not diﬀ er in the candesartan and 
placebo groups (table 5). The safety population was 
deﬁ ned as all patients who received at least one dose of 
randomised investigational product and for whom any 
post-dose data were available. Three patients were 
excluded from the safety population as randomised 
investigational products were not dispensed (two in the 
candesartan group and one in the placebo group, 
respectively). The four most common adverse events 
were hypertension, headache, inﬂ uenza, and pain in 
extremities. Permanent discontinuation and mortality 
proportions did not diﬀ er by treatment allocation.
Discussion 
We found that treatment with the angiotensin receptor 
blocker candesartan during a 4 year trial resulted in a 
non-signiﬁ cant reduction in progression of retinopathy, 
the primary endpoint. At the end of the trial, those 
participants on candesartan had a signiﬁ cantly favourable 
change in retinopathy levels, a prespeciﬁ ed outcome 
measure, compared with placebo. We also showed a 
signiﬁ cant regression of retinopathy, the main secondary 
endpoint, in the candesartan-treated group compared 
with those on placebo. 
Candesartan did not aﬀ ect the incidence of proliferative 
diabetic retinopathy or clinically signiﬁ cant macular 
oedema, or both. About a ﬁ fth of participants had these 
manifestations; this proportion is higher than might be 
seen clinically, and indicates our use of a more sensitive 
research purpose grading system.
The treatment curves for progression of retinopathy in 
patients in this study only began to diverge after 4 years 
of follow-up. In the UK Prospective Diabetes Study 
(UKPDS),28 no treatment eﬀ ect on progression was 
observed at 1·5 years in those with retinopathy at 
baseline. A signiﬁ cant eﬀ ect was only recorded at 
4·5 years.28 In the ABCD trial,6 blood pressure at baseline 
was similar to values recorded in our study, but a mean 
treatment diﬀ erence of 11 mm Hg systolic pressure was 
achieved in the group given intensive treatment compared 
with those given moderate treatment over 5·3 years 
Hazard ratio (95% CI) p value
Unadjusted 1·34 (1·08–1·68) 0·009
Adjusted* 1·38 (1·11–1·73) 0·004
Adjusted† 1·33 (1·06–1·67) 0·015
*Adjusted for the following baseline characteristics: retinopathy level, duration of diabetes, urinary albumin excretion 
rate, HbA1c, antihypertensive treatment, and systolic blood pressure. †Adjusted for the following baseline 
characteristics: retinopathy level, duration of diabetes, urinary albumin excretion rate, HbA1c, antihypertensive 
treatment, and systolic blood pressure as a time-dependent covariate.
Table 4: Estimated hazard ratios for candesartan versus placebo for time to regression of retinopathy 
(intention-to-treat population)
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Figure 5: Cumulative proportion of patients with regression of retinopathy, grouped by retinopathy level at 
baseline 
(A) Microaneurysms only. (B) Mild non-proliferative diabetic retinopathy. (C) Moderate to moderately severe 
retinopathy.
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(using either an angiotensin-converting enzyme inhibitor 
or a calcium-channel blocker). Progression of two steps 
was also lower in the intensive blood pressure group 
(34% vs 46%)—ie, a 12% absolute reduction.6 We recorded 
a 2% (19% vs 17%) absolute reduction in progression of 
retinopathy by three or more steps. Although this 
absolute reduction was smaller than that reported in the 
ABCD trial, it is in keeping with the much smaller 
diﬀ erence in mean blood pressure associated with 
candesartan treatment.
However, diﬀ erences between studies limit such 
comparisons. Both the UKPDS and the ABCD trials used 
a two-step change on the ETDRS scale as their retinopathy 
endpoint; included patients who were hypertensive; and 
maintained diﬀ erent blood pressure in each treatment 
group. We enrolled patients who were either normotensive 
or treated hypertensive, and did not aim to treat blood 
pressure to a given target, although a small diﬀ erence in 
the range of 2–4 mm Hg was seen between the 
candesartan and placebo groups. Analysis of progression 
of retinopathy, adjusting for blood pressure at baseline 
and during the course of the trial, did not materially 
change HRs. However, small diﬀ erences between 
treatment groups in resting blood pressure can allow 
large treatment diﬀ erences in diurnal patterns of blood 
pressure,29 and we therefore cannot robustly conclude 
that any beneﬁ cial eﬀ ect of candesartan on retinopathy is 
independent of its eﬀ ect on lowering blood pressure.
We showed that candesartan treatment was associated 
with a 34% increase in regression of retinopathy. In a 
subgroup analysis, patients with mild retinopathy 
(level 35) regressed signiﬁ cantly, whereas the eﬀ ect on 
more severe retinopathy was less evident. The robustness 
of our criteria for regression (either a three-step decrease 
in severity of retinopathy on the ETDRS scale from 
baseline at one time point, or a two-step decrease 
sustained on two consecutive visits), along with its 
independence of potential confounders, suggest that this 
treatment eﬀ ect on regression is a genuine ﬁ nding. 
Candesartan has been shown to induce regression of 
end-organ damage at other sites, including left-ventricular 
hypertrophy and intima-media thickness,30,31 and its eﬀ ect 
on retinopathy might represent another facet of its 
activity. This is of particular interest in light of recent 
reports that diabetic retinopathy is associated with 
increased cardiovascular mortality,32–34 reduced coronary 
reactivity,35 and poorer prognosis of coronary 
revascularisation procedures.36,37 Diabetic retinopathy 
might thus be a readily visible marker of diﬀ use 
endothelial damage at microvascular and macrovascular 
levels; however, no clinical trial data show that agents 
able to induce regression of retinopathy have similar 
beneﬁ cial eﬀ ects on other cardiovascular endpoints. 
Our study design did not enable us to identify the 
mechanism by which blocking the renin–angiotensin 
system could aﬀ ect regression of diabetic retinopathy. As 
discussed, this could simply be due to lowering of blood 
pressure. However, a local renin–angiotensin system 
operates in the eye,38,39 and is upregulated in active 
retinopathy.40,41 Angiotensin II might directly, or by 
upregulation of growth factors such as VEGF, induce 
exudation from the retinal capillaries,42 causing 
appearance of haemorrhages, hard exudates, and 
thickening of the retina in the macular area.43 We speculate 
that the regression of retinopathy associated with 
candesartan treatment could in part be due to a reduction 
of the exudative process occurring at an early stage. At a 
more advanced stage, at which ischaemic changes are 
predominant, retinopathy might have reached a so-called 
point of no return, indicating that treatment with an 
angiotensin receptor blocker is most beneﬁ cial at relatively 
early stages of the disease. This suggestion is supported 
by the lack of eﬀ ectiveness of losartan on macular oedema, 
in a short, small pilot study.44 
Experimental studies have indicated that candesartan 
has a dose-dependent organ protective eﬀ ect.45,46 We chose 
a relatively high dose, aiming at 32 mg per day. Rates of 
adverse event rates did not diﬀ er in the treatment groups, 
which supports the safety of the drug at the administered 
dose.47,48 
Treatment with the angiotensin receptor blocker 
candesartan over a 4 year trial reduced the primary 
endpoint of progression of retinopathy by 13% versus 
placebo in normoalbuminuric, normotensive, or 
controlled hypertensive patients with type 2 diabetes, 
although this reduction was not signiﬁ cant. Patients 
given candesartan were a third more likely to experience 
regression of retinopathy (a secondary endpoint) and 
more likely to end the trial with a more favourable 
retinopathy status (a prespeciﬁ ed outcome measure), due 
both to greater regression and lesser progression. These 
results suggest that treatment with candesartan in type 2 
diabetic patients with mild to moderate retinopathy could 
induce improvement of retinopathy.
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Candesartan (N=949) Placebo (N=953)
All adverse events 796 (84%) 786 (83%) 
Hypertension 124 (13%) 173 (18%)
Headache 79 (8%) 94 (10%)
Inﬂ uenza 77 (8%) 83 (9%)
Pain in extremities 79 (8%) 79 (8%)
Discontinued study 
medication because of 
adverse event
37 (4%) 42 (4%)
Death 37 (4%) 35 (4%)
Data are number of patients (%). 
Table 5: Adverse events for the safety population
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